drugset / Trial / NCT00812266

Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)

NCT00812266

Phase 3 Terminated 281 enrolled Danish Oncological Lung Cancer Group
RandomizedParallel-groupOpen-labelTreatment

Summary

Randomised trial comparing standard chemotherapy with carboplatin and etoposide with a combination of topotecan and cisplatin in patients with inoperable lung cancer of small cell type.

Timeline

Start
2006-01
Primary completion
2013-12
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carboplatin Small molecule 5 unknown Intravenous
Subject Cisplatin Other / unclassified 50 mg/m2 Intravenous
Comparator Etoposide Small molecule 120 mg/m2 Intravenous
Subject Topotecan Small molecule 2 mg/m2 Intravenous